This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Day, M. L. Articles by Needleman, P. Search for Related Content PubMed PubMed Citation Articles by Day, M. L. Articles by Needleman, P.

Hypertension, Vol 9, 485-491, Copyright © 1987 by American Heart Association

ARTICLES

Ventricular atriopeptin. Unmasking of messenger RNA and peptide synthesis by hypertrophy or dexamethasone

ML Day, D Schwartz, RC Wiegand, PT Stockman, SR Brunnert, HE Tolunay, MG Currie, DG Standaert and P Needleman

Left ventricular hypertrophy or treatment with dexamethasone caused a 2.5-fold to threefold increase in both immunoreactive atriopeptin (AP) and AP messenger RNA (mRNA), primarily in left ventricular tissue. The combined treatments increased immunoreactive AP and AP mRNA more than either treatment alone. In the animals in which cardiac hypertrophy had been produced by abdominal aortic constriction, there was a decrease in atrial levels of AP and an increase in plasma levels of immunoreactive AP. The increase in left ventricular immunoreactive AP was confirmed by immunohistochemical staining of tissue from hypertrophied and/or dexamethasone-treated rats. The mRNA accumulated in the left ventricle was identical to atrial AP mRNA, as judged by transcriptional start site and by size on Northern blots. Because the mass of ventricular tissue is substantially greater than that of atrial tissue, the induced mRNA levels may represent a total abundance approaching one third of the total AP mRNA in the atria. High performance liquid chromatographic purification of ventricular extracts primarily demonstrated the presence of the high molecular precursor and small amounts of C- terminal peptide AP. Induction of ventricular AP (mRNA and peptide) may represent regression of the tissue to an earlier developmental form. These data provide a unique example of regulation of AP biosynthesis in nonatrial tissue.

This article has been cited by other articles:

				P. Yue, T. Arai, M. Terashima, A. Y. Sheikh, F. Cao, D. Charo, G. Hoyt, R. C. Robbins, E. A. Ashley, J. Wu, et al. Magnetic resonance imaging of progressive cardiomyopathic changes in the db/db mouse Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2106 - H2118. [Abstract] [Full Text] [PDF]

				L. J Ellmers, N. J A Scott, J. Piuhola, N. Maeda, O. Smithies, C. M Frampton, A M. Richards, and V. A Cameron Npr1-regulated gene pathways contributing to cardiac hypertrophy and fibrosis J. Mol. Endocrinol., February 1, 2007; 38(2): 245 - 257. [Abstract] [Full Text] [PDF]

				M. D. Jarvis, M. T. Rademaker, L. J. Ellmers, M. J. Currie, J. L. McKenzie, B. R. Palmer, C. M. Frampton, A. M. Richards, and V. A. Cameron Comparison of infarct-derived and control ovine cardiac myofibroblasts in culture: response to cytokines and natriuretic peptide receptor expression profiles. Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1952 - H1958. [Abstract] [Full Text] [PDF]

				A. C. Houweling, M. M. van Borren, A. F.M. Moorman, and V. M. Christoffels Expression and regulation of the atrial natriuretic factor encoding gene Nppa during development and disease Cardiovasc Res, September 1, 2005; 67(4): 583 - 593. [Abstract] [Full Text] [PDF]

				M. M. Kittleson, K. M. Minhas, R. A. Irizarry, S. Q. Ye, G. Edness, E. Breton, J. V. Conte, G. Tomaselli, J. G. N. Garcia, and J. M. Hare Gene expression analysis of ischemic and nonischemic cardiomyopathy: shared and distinct genes in the development of heart failure Physiol Genomics, May 11, 2005; 21(3): 299 - 307. [Abstract] [Full Text] [PDF]

				V. A. Cameron and L. J. Ellmers Minireview: Natriuretic Peptides during Development of the Fetal Heart and Circulation Endocrinology, June 1, 2003; 144(6): 2191 - 2194. [Abstract] [Full Text] [PDF]

				A. M. Devlin, N. Solban, S. Tremblay, J. Gutkowska, W. Schurch, S. N. Orlov, R. Lewanczuk, P. Hamet, and J. Tremblay HCaRG is a novel regulator of renal epithelial cell growth and differentiation causing G2M arrest Am J Physiol Renal Physiol, April 1, 2003; 284(4): F753 - F762. [Abstract] [Full Text] [PDF]

				L. J. Ellmers, J. W. Knowles, H.-S. Kim, O. Smithies, N. Maeda, and V. A. Cameron Ventricular expression of natriuretic peptides in Npr1-/- mice with cardiac hypertrophy and fibrosis Am J Physiol Heart Circ Physiol, August 1, 2002; 283(2): H707 - H714. [Abstract] [Full Text] [PDF]

				D. L. Vesely, G. I. San Miguel, I. Hassan, and D. D. Schocken Atrial Natriuretic Hormone, Vessel Dilator, Long-Acting Natriuretic Hormone, and Kaliuretic Hormone Decrease the Circulating Concentrations of CRH, Corticotropin, and Cortisol J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4244 - 4249. [Abstract] [Full Text] [PDF]

				M. O. Boluyt and O. H.L. Bing Matrix gene expression and decompensated heart failure: The aged SHR model Cardiovasc Res, May 1, 2000; 46(2): 239 - 249. [Abstract] [Full Text] [PDF]

				S. Kaddoura, J. D. Firth, K. R. Boheler, P. H. Sugden, and P. A. Poole-Wilson Endothelin-1 Is Involved in Norepinephrine-Induced Ventricular Hypertrophy In Vivo : Acute Effects of Bosentan, an Orally Active, Mixed Endothelin ETA and ETB Receptor Antagonist Circulation, June 1, 1996; 93(11): 2068 - 2079. [Abstract] [Full Text]

				L. Cao and D. G. Gardner Natriuretic Peptides Inhibit DNA Synthesis in Cardiac Fibroblasts Hypertension, February 1, 1995; 25(2): 227 - 234. [Abstract] [Full Text]